Overview Financials News + Filings Key Docs Charts Ownership
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
NeuroDerm Ltd. (NDRM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/18/2017 |
6-K
| Quarterly results |
| 09/12/2017 |
6-K
| Quarterly results |
| 08/17/2017 |
6-K
| Quarterly results |
| 08/03/2017 |
6-K
| Quarterly results|
Docs:
|
"FORM 6-K",
"NeuroDerm Announces Second Quarter 2017 Financial Results REHOVOT, Israel – August 3, 2017 – NeuroDerm Ltd. , a clinical stage pharmaceutical company developing drug-device combinations for central nervous system disorders, today announced financial results for the second quarter ended June 30, 2017. Recent Highlights · On July 24, 2017, NeuroDerm entered into a definitive agreement to be acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 billion in cash. A special meeting of shareholders to approve the transaction is expected to be held on September 12, 2017. Assuming typical regulatory and shareholder approval timeframes, NeuroDerm currently anticipates the transaction will close in the fourth quarter of 2017. · On June 6, 2017, NeuroDerm announced that the main de..." |
|
| 07/24/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 06/30/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 06/09/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]|
Docs:
|
"FORM 6-K",
"NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster Session at the 21st International Congress of Parkinson’ s Disease and Movement Disorders -ND0612H achieved a complete reduction of OFF-time to zero in 42% of patients treated for 24 hours - - Statistically significant and clinically meaningful reduction in OFF-time and increase in the portion of patients "ON" by 8:00am- REHOVOT, Israel – June 5, 2017 – NeuroDerm Ltd. , a clinical stage pharmaceutical company developing drug-device combinations for central nervous system disorders, today announced final data from trial 006. Sheila Oren, MD, MBA, Chief Medical Officer at NeuroDerm will present the final results from this trial in a poster titled, “Safety, efficacy and tolerability of continuous SC LD/CD infusion in PD...",
"European Medicines Agency Accepts Design of NeuroDerm’ s ND0612 Phase III iNDiGO Efficacy Trial REHOVOT, Israel – June 6, 2017 – NeuroDerm Ltd. , a clinical stage pharmaceutical company developing drug-device combinations for central nervous system disorders, today announced that it has received a Scientific Advice Letter from the Scientific Advice Working Party of the European Medicines Agency . The letter accepts the main design elements suggested by NeuroDerm for the amended iNDiGO phase III efficacy trial , including study population and primary and secondary endpoints, as well as the suggested statistical analysis approach. The EMA suggested that NeuroDerm’ s planned clinical and regulatory development program may be adequate to support a benefit-risk evaluation of ND0612 for the trea...",
"NeuroDerm Presents Six Posters at the 21st International Congress of Parkinson’ s Disease and Movement Disorders - Includes demographic data from the ND0612 trial 006 and complete data from a Phase 1 pharmacokinetic study of ND0701 - REHOVOT, Israel – June 8, 2017 – NeuroDerm Ltd. , a clinical stage pharmaceutical company developing drug-device combinations for central nervous system disorders, today announced that it will present six posters related to its clinical pipeline in a poster session today from 1:15 p.m. to 2:45 p.m. PT at the 21st International Congress of Parkinson’ s Disease and Movement Disorders. The Congress is taking place June 4-8, 2017 in Vancouver, B.C. Tami Rachmilewitz, MD, Medical Director at NeuroDerm will present complete demographic data from trial 006 in an abst..." |
|
| 05/12/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 04/03/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 03/03/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 03/02/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 02/01/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 01/26/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 12/27/2016 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 12/08/2016 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 12/05/2016 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 11/14/2016 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 09/29/2016 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 08/30/2016 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 07/28/2016 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 06/15/2016 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 05/26/2016 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 05/09/2016 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 04/22/2016 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 04/04/2016 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
|
|